Clinical trialNCT04381468CompletedPhase 1/PHASE2Interventional

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

SponsorVaccinex Inc.Enrollment50Alzheimer Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Eric Siemers, MD
Vaccinex Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Pacific Research Network, Inc
San Diego, California, United States
Georgetown University
Washington D.C., District of Columbia, United States
Brain Matters Research
Delray Beach, Florida, United States
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida, United States
Jem Research Institute
Lake Worth, Florida, United States
Premiere Research Institute of Palm Beach, Neurology
Palm Beach, Florida, United States
Brain Matters Research
Stuart, Florida, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
University of Kansas Medical Center
Fairway, Kansas, United States
Neurological Associates of Albany
Albany, New York, United States
Dent Neurological Associates
Amherst, New York, United States
Columbia University Irving Medical Center
New York, New York, United States
University of Rochester Medical Center
Rochester, New York, United States
Re-Cognition Health
Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PepinemabPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 22 Jul 2021
Primary completion: 5 Jun 2024
Completion: 5 Jun 2024
Last update posted: 22 Aug 2024
Registered enrollment: 50
Registry id: NCT04381468

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.